Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of DS-8201a in advanced breast cancer with biomarker analysis
2018-004868-57Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jun 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in breast cancer (3 cohorts), sponsored by Unicancer. Primary endpoint: Confirmed best objective response rate. Started Jun 2019; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-004868-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004868-57.